Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes
Phase 4
300
about 4.7 years
18+
1 site in TX
About this study
This trial is testing how different genes affect how people respond to GLP-1, a hormone that helps lower blood sugar. The goal is to find out if certain genetic variations make some people more or less likely to benefit from GLP-1 treatment.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Semaglutide
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
semaglutide (GLP-1 agonist; stimulates insulin release)
oral (Oral Tablet)
Primary: Gene expression changes for minor variants of eQTLs for CHST3, Gene expression changes for minor variants of eQTLs for CNR1, Gene expression changes for minor variants of eQTLs for CTRB1, Gene expression changes for minor variants of eQTLs for CTRB2, Gene expression changes for minor variants of eQTLs for GLP1R, Gene expression changes for minor variants of eQTLs for KCNQ1, Gene expression changes for minor variants of eQTLs for MTNR1B, Gene expression changes for minor variants of eQTLs for SORCS1
Secondary: Change in hemoglobin A1C, Mean change in C-peptide Area Under the Curve (AUC), Mean change in glucose Area Under the Curve (AUC), Mean change in insulin Area Under the Curve (AUC)